167 related articles for article (PubMed ID: 32655836)
1. IQGAP1 control of centrosome function defines distinct variants of triple negative breast cancer.
Osman MA; Antonisamy WJ; Yakirevich E
Oncotarget; 2020 Jun; 11(26):2493-2511. PubMed ID: 32655836
[TBL] [Abstract][Full Text] [Related]
2. The Antipsychotic Drug Haldol Modulates IQGAP1-Signaling and Inhibits Cell Proliferation in Triple Negative Breast Cancer Cell Lines.
Iyer VJ; Osman MA
MicroPubl Biol; 2023; 2023():. PubMed ID: 37215640
[TBL] [Abstract][Full Text] [Related]
3. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract][Full Text] [Related]
4. Rampant centrosome amplification underlies more aggressive disease course of triple negative breast cancers.
Pannu V; Mittal K; Cantuaria G; Reid MD; Li X; Donthamsetty S; McBride M; Klimov S; Osan R; Gupta MV; Rida PC; Aneja R
Oncotarget; 2015 Apr; 6(12):10487-97. PubMed ID: 25868856
[TBL] [Abstract][Full Text] [Related]
5. Saikosaponin D from Radix Bupleuri suppresses triple-negative breast cancer cell growth by targeting β-catenin signaling.
Wang J; Qi H; Zhang X; Si W; Xu F; Hou T; Zhou H; Wang A; Li G; Liu Y; Fang Y; Piao HL; Liang X
Biomed Pharmacother; 2018 Dec; 108():724-733. PubMed ID: 30248540
[TBL] [Abstract][Full Text] [Related]
6. [Molecular mechanisms of resistance to phosphatidyl inositol 3-kinase inhibitors in triple-negative breast cancer cells].
Zhang WL; Ma WJ; Chen S; Wu XZ; Zhang HR; Zhang JH
Zhonghua Zhong Liu Za Zhi; 2016 Aug; 38(8):578-88. PubMed ID: 27531477
[TBL] [Abstract][Full Text] [Related]
7. MiR-25-3p promotes the proliferation of triple negative breast cancer by targeting BTG2.
Chen H; Pan H; Qian Y; Zhou W; Liu X
Mol Cancer; 2018 Jan; 17(1):4. PubMed ID: 29310680
[TBL] [Abstract][Full Text] [Related]
8. A Provocative Molecular Link between Mammographic Density and BRCA1-loss associated TNBC.
Xu J; Olusola G; Footman A; Hansen N; Cheriyan AM; Koganti K; Reddy V; Yezdani S; Eddy V; De'smond H; Bakinde N; Okoli J; Oprea G; Gundry K; Reddy ESP; Rao VN
Int J Hum Genet Genet Disord; 2019; 1(1):1-8. PubMed ID: 33860286
[TBL] [Abstract][Full Text] [Related]
9. [Expression and significance of Nek2B and β-catenin in triple negative breast cancer].
Yan WP; Shen HH; Ma WX; Wang ZY; Shang LF; Shen NN; Qi GY; Wei R; Zhang XQ; Wang C
Zhonghua Bing Li Xue Za Zhi; 2020 May; 49(5):424-429. PubMed ID: 32392924
[No Abstract] [Full Text] [Related]
10. Strictinin, a novel ROR1-inhibitor, represses triple negative breast cancer survival and migration via modulation of PI3K/AKT/GSK3ß activity.
Fultang N; Illendula A; Chen B; Wu C; Jonnalagadda S; Baird N; Klase Z; Peethambaran B
PLoS One; 2019; 14(5):e0217789. PubMed ID: 31150511
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological and Molecular Study of Triple-Negative Breast Cancer in Algerian Patients.
Gaceb H; Cherbal F; Bakour R; Ould-Rouis A; Mahfouf H
Pathol Oncol Res; 2018 Apr; 24(2):297-308. PubMed ID: 28478614
[TBL] [Abstract][Full Text] [Related]
12. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
[TBL] [Abstract][Full Text] [Related]
13. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
14. A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling.
Wang DY; Gendoo DMA; Ben-David Y; Woodgett JR; Zacksenhaus E
Breast Cancer Res; 2019 Jan; 21(1):18. PubMed ID: 30704524
[TBL] [Abstract][Full Text] [Related]
15. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
[TBL] [Abstract][Full Text] [Related]
16. Ras GTPase-Activating-Like Protein IQGAP1 (IQGAP1) Promotes Breast Cancer Proliferation and Invasion and Correlates with Poor Clinical Outcomes.
Zeng F; Jiang W; Zhao W; Fan Y; Zhu Y; Zhang H
Med Sci Monit; 2018 May; 24():3315-3323. PubMed ID: 29779034
[TBL] [Abstract][Full Text] [Related]
17. HePTP promotes migration and invasion in triple-negative breast cancer cells via activation of Wnt/β-catenin signaling.
Yu L; Wang C; Pan F; Liu Y; Ren X; Zeng H; Shi Y
Biomed Pharmacother; 2019 Oct; 118():109361. PubMed ID: 31545274
[TBL] [Abstract][Full Text] [Related]
18. Modulation of Mitochondrial ERβ Expression Inhibits Triple-Negative Breast Cancer Tumor Progression by Activating Mitochondrial Function.
Song IS; Jeong YJ; Jeong SH; Kim JE; Han J; Kim TH; Jang SW
Cell Physiol Biochem; 2019; 52(3):468-485. PubMed ID: 30873822
[TBL] [Abstract][Full Text] [Related]
19. Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia.
Mahfoudh W; Bettaieb I; Ghedira R; Snoussi K; Bouzid N; Klayech Z; Gabbouj S; Remadi Y; Hassen E; Bouaouina N; Zakhama A
J Transl Med; 2019 Apr; 17(1):123. PubMed ID: 30975216
[TBL] [Abstract][Full Text] [Related]
20. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM
Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724
[No Abstract] [Full Text] [Related]
[Next] [New Search]
